Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Cash & Current Investments data on record, last reported at $86.6 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 69.09% year-over-year to $86.6 million; the TTM value through Jun 2025 reached $304.6 million, up 9.41%, while the annual FY2025 figure was $86.6 million, 69.09% down from the prior year.
  • Cash & Current Investments reached $86.6 million in Q4 2025 per MIRM's latest filing, down from $93.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $434.9 million in Q3 2022 and bottomed at $65.9 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $245.2 million, with a median of $279.3 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: surged 129.3% in 2024, then crashed 78.26% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $256.5 million in 2021, then decreased by 1.88% to $251.7 million in 2022, then increased by 13.75% to $286.3 million in 2023, then fell by 2.1% to $280.3 million in 2024, then crashed by 69.09% to $86.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $86.6 million in Q4 2025, $93.5 million in Q3 2025, and $304.6 million in Q2 2025.